# Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)

> **NCT02759601** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Queen Mary University of London** · enrollment: 69 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Tefinostat

## Key facts

- **NCT ID:** NCT02759601
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2018-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02759601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02759601, "Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02759601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*